Greek Registry - Familial Hypercholesterolaemia

Last updated: September 14, 2020
Sponsor: Hellenic College of Treatment of Atherosclerosis
Overall Status: Active - Recruiting

Phase

N/A

Condition

Familial Hypercholesterolemia

Hypercholesterolemia

Dyslipidemia

Treatment

N/A

Clinical Study ID

NCT03140605
2017-HPLS-IIS
  • Ages 18-80
  • All Genders

Study Summary

Familial hypercholesterolemia (FH) [heterozygous (heFH) or homozygous FH (hoFH)] is a common genetic disorder, characterized by elevated plasma low density lipoprotein (LDL) cholesterol concentration leading (if untreated) to cholesterol deposits in the corneas, eyelids and extensor tendons, rapidly progressing vascular disease, and aortic valve disease.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • both genders

  • >18 years, <80 years

  • door to door enrolment

  • eligible to sign informed consent

Exclusion

Exclusion Criteria:

  • <18 years, >80 years

  • deny to sign informed consent

Study Design

Total Participants: 1000
Study Start date:
January 10, 2017
Estimated Completion Date:
December 10, 2020

Study Description

In contrast, timely recognition and effective treatment of FH can result in a significant improvement in clinical outcomes. The problem is that that majority of individuals with FH are unaware of their disease, particularly that the disease remains silent for many years. In most countries around the world <5% of individuals with FH are identified .

Until lately the prevalence of heFH was traditionally considered to be ~ 1:500 individuals , although clinical and genetic studies suggest that heFH affects ~ 1:200-250 individuals . Thus, the aim of the Hellenic College of Treatment of Atherosclerosis (HCAT) is to 1). Evaluate the prevalence of FH in Greece (FHG-Registry) and 2). To inform population of FH disease.

Connect with a study center

  • Onassis Cardiology Hospital

    Athens,
    Greece

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.